

# Antidiabetic exendin-4 activates apoptotic pathway and inhibits growth of breast cancer cells

Güzin Fidan-Yaylı<sup>1</sup> · Yavuz Dodurga<sup>2</sup> · Mücahit Seçme<sup>2</sup> · Levent Elmas<sup>2</sup>

Received: 21 July 2015 / Accepted: 17 September 2015 / Published online: 24 September 2015  
© International Society of Oncology and BioMarkers (ISOBM) 2015

**Abstract** Exendin-4 is a GLP-1 analog used for the treatment of type 2 diabetes mellitus in its synthetic form. As women with diabetes have higher breast cancer incidence and mortality, we examined the effect of the incretin drug exendin-4 on breast cancer cells. The aim of the study is to investigate anticancer mechanism of exendin-4 in MCF-7 breast cancer cells. Cytotoxic effects of exendin-4 were determined by XTT assay. IC<sub>50</sub> dose in MCF-7 cells were detected as 5 µM at 48th hour. Gene messenger RNA (mRNA) expressions were evaluated by real-time PCR. According to results, *caspase-9*, *Akt*, and *MMP2* expression was reduced in dose group cells, compared with the control group cells. *p53*, *caspase-3*, *caspase-8*, *caspase-10*, *BID*, *DR4*, *DR5*, *FADD*, *TRADD*, *PARP*, *PTEN*, *PUMA*, *NOXA*, *APAF*, *TIMP1*, and *TIMP2* expression was increased in dose group cells, compared with the control group cells. Effects of exendin-4 on cell invasion, colony formation, and cell migration were detected by Matrigel chamber, colony formation assay, and wound-healing assay, respectively. To conclude, it is thought that exendin-4 demonstrates anticarcinogenesis activity by effecting apoptosis, invasion, migration, and colony formation in MCF-7 cells. Exendin-4 may be a therapeutic agent for treatment of breast cancer as single or in combination with other agents. More detailed researches are required to define the pathways of GLP-1 effect

on breast cancer cells because of the molecular biology of breast cancer that involves a complex network of interconnected signaling pathways that have role in cell growth, survival, and cell invasion.

**Keywords** Exendin-4 · Glucagon-like peptide · Breast cancer · Diabetes

## Abbreviations

DM	Diabetes mellitus
GLP-1	Glucagon-like peptide-1
GPCR	G protein-coupled receptor
IGF-1	Insulin-like growth factor 1
XTT	2,3-Bis-(2-Metoksi-4-nitro-5-sülfofenil)-2H-tetrazolium-5-carboxanilide

## Introduction

In addition to the known complications of diabetes, there is emerging evidence that diabetes mellitus (DM) patients may face a higher risk of developing cancer [1] and a higher cancer mortality [2], particularly for breast cancer [2, 3]. Various factors may be related to obesity, diabetes, and breast cancer risk, contain activation of insulin and insulin-like growth factor 1 (IGF-1) pathways, altered regulation of endogenous sex hormones, and altered levels of adipocytokines [4–9].

Glucagon-like peptide (GLP)-1 is situated in the incretin system and secreted from intestinal L cells. It demonstrates its actions via the GLP-1 receptor (GLP-1R)—a G protein-coupled receptor (GPCR) expressed on pancreatic β cells and other tissues, including the brain, heart, and smooth muscle [9, 10]. Different activities of GLP-1 have been defined to

✉ Yavuz Dodurga  
yavuzdodurga@gmail.com

<sup>1</sup> Department of Endocrinology and Metabolic Diseases, Faculty of Medicine, Pamukkale University, Denizli, Turkey

<sup>2</sup> Department of Medical Biology and Genetics, Faculty of Medicine, Pamukkale University, Denizli, Turkey

date. For instance, GLP-1 stimulates insulin secretion from  $\beta$  cells, modulates their proliferation and differentiation, and inhibits their apoptosis [9, 11]. Furthermore, GLP-1 is a strong inhibitor of gastric emptying and a promoter of satiety; sustained activation of the GLP-1R is related to weight loss [12]. Some researches suggest that GLP-1 may increase insulin sensitivity in peripheral tissues [13, 14]. Exendin-4 is a more stable GLP-1 analog [15] currently used for the treatment of type 2 diabetes mellitus in its synthetic form exenatide [16].

GLP-1-based therapy on breast cancer may have significant clinical implications because of the fact that type 2 DM, obesity, and breast cancer commonly appear together [2, 16]. Recently, several studies have been reported on the effects of GLP-1 and exendin-4 on cancer cells. In these studies, an inhibitory effect of exendin-4 on cell growth in colon CT26 [17] and in MCF-7 and MDA-MB-231 breast [9] cancer cells has been reported. We aimed to evaluate the effects of exenatide on breast cancer cell proliferation and viability; besides, this evaluates the effects on cell migration, cell invasion, and colony formation capacity in this study.

## Material and methods

### Cell culture

MCF-7 human breast cancer cell (obtained from ATCC, USA) line was used in this study. MCF-7 cells were grown in DMEM medium supplemented with 2 mM L-glutamine, penicillin (20 units/ml), streptomycin (20  $\mu$ g/ml), and 10 % (v/v) heat-inactivated fetal calf serum at 37 °C in a saturated humidity atmosphere containing 95 % air and 5 % CO<sub>2</sub>. MCF-7 cells were treated with 0.25, 0.5, 1, 1.5, 2, 3, 5, 7.5, and 10  $\mu$ M exendin-4 by solving in medium during 72 h, considering a time- and dose-dependent manner.

### Cytotoxicity assay

Cytotoxicity assays and determination of IC<sub>50</sub> dose of exendin-4 in MCF-7 cells were performed by using trypan blue dye exclusion test and XTT assay as indicated in the manufacturers' instruction.

### XTT assay

Cells were seeded in 96-well tissue culture plates and incubated for 24 h without reagent. After addition of reagents, cells were incubated for 24, 48, and 72 h and cell viability was assessed by using XTT (2,3-bis-(2-Metoksi-4-nitro-5-sülfofenil)-2H-tetrazolium-5-carboxanilide) mixture as recommended by the supplier. Formazan formation was quantified spectrophotometrically at 450 nM (reference wavelength 630 nM)

using a microplate reader. Viability was calculated using the background-corrected absorbance as follows:

$$\text{Viability(\%)} = \text{A of experiment well} / \text{A of control well} \times 100$$

### RNA isolation and real-time PCR

Total RNA was isolated from the cells exposed to IC<sub>50</sub> doses of exendin-4 with TRIzol Reagent (Invitrogen, USA) according to the manufacturer's instructions. Complementary DNA (cDNA) synthesis was performed by using Transcriptor First-Strand cDNA Synthesis Kit (Roche, Germany). *p53*, *caspase-3*, *caspase-9*, *caspase-8*, *caspase-10*, *Bcl-2*, *BCL-XL*, *BID*, *DR4*, *DR5*, *FADD*, *TRADD*, *PARP*, *APAF*, *Bax*, *Akt*, *PTEN*, *PUMA*, *NOXA*, *MMP2*, *MMP9*, *TIMP1*, *TIMP2* gene expression was performed on real-time RT-PCR according to the SYBR Green qPCR Master Mix (Thermo Scientific, USA) protocol. RT-PCR assay was performed using gene-specific primers. The expression results were proportioned to the *GAPDH* gene (housekeeping gene) expressions to calculate relative expression ratios. Primer sequences were given in Table 1.

### Cell migration and invasion assay

Invasion activities of control and dose group cells were determined according to the BioCoat Matrigel Invasion Chamber guide (BD Biosciences). The cells with serum-free DMEM were seeded at a density of  $2 \times 10^5$  cells/well onto the upper chambers of Matrigel-coated filter inserts, and serum-containing DMEM (500  $\mu$ l) was added to the lower chambers. Then, the cells were incubated at 37 °C for 24 h. After of incubation, filter inserts were removed from the wells. The cells on the upper surface of the filter were wiped with a cotton swab. Filters were fixed with methanol for 10 min and stained with crystal violet. The cells that invaded the lower surface of the filter were counted under a light microscope. Each experiment was repeated three times. Percentage of invasion was calculated using control and Matrigel membrane cell count as follows:

$$\text{Invasion(\%)} = \frac{\text{The number of cells in matrigel matrix basement membrane}}{\text{The number of cells in control membrane}} \times 100$$

### Colony assay

For colony formation analysis, the cells were digested with trypsin, counted using trypan blue dye exclusion test, and seeded in six-well plates at a density of  $10^3$  cells per well. The medium was changed every 3 days for 15 days until visible colonies formed. Colonies were fixed methanol for 10 min and stained with crystal violet.

**Table 1** Primer sequences of the genes used in this study

Name	Primer sequence
<i>APAF</i>	F: ATGAGCCCACTCAACAGCAA R: GTCCTTACACTGGAAGAAGAGAC
<i>BAX</i>	F: AGAGGATGATTGCCGCCGT R: CAACCACCTGGTCTTGATC
<i>Caspase-3</i>	F: GCAGCAAACCTCAGGAAAC R: TGTCGGCATACTGTTTCAGCA
<i>BCL-2</i>	F: TTGGCCCCGTTGCTT R: CGGTATATCGTACCCCGTTCTC
<i>GAPDH</i>	F: TTCTATAAATTGAGCCCGCAGCC R: CCGTTGACTCCGACCTTCAC
<i>Caspase-9</i>	F: GGCTGTCTACGGCACAGATGGA R: CTGGCTCGGGTTACTGCCAG
<i>p21</i>	F: TGGAGACTCTCAGGGTCGAAA R: GGCGTTGGAGTGGTAGAAAATC
<i>p53</i>	F: ATCTACAAGCAGTCACAGCACAT R: GTGGTACAGTCAGAGCCAACC
<i>PTEN</i>	F: CCCAGACATGACAGCCATC R: TCTGCAGGAAATCCCATAGC
<i>PARP</i>	F: ACACCCCTTGACGTACTTC R: GATGGTTCTCTGAGCTTCG
<i>PUMA</i>	F: GACCTCAACGCACAGTACGAG R: AGGAGTCCCATGATGAGATTGT
<i>NOXA</i>	F: ACCAAGCCGGATTGCGATT R: ACTTGCACTTGTCTCTCGTGG
<i>BID</i>	F: CCTACCCTAGAGACATGGAGAAG R: TTTCTGGCTAAGCTCCTCACG
<i>AKT</i>	F: CAACTTCTCTGTGGCGCAGTG R: GACAGGTGGAAGAACAGCTCG
<i>BCL-XL</i>	F: GGTCGCATTGTGGCCTTTTTTC R: TGCTGCATTGTCCCATAGAG
<i>DR4 (TNFRSF10A)</i>	F: GCGGGGAGGATTGAACCAC R: CGACGACAAACTTGAAGGTCTT
<i>DR5 (TNFRSF10B)</i>	F: ACAGTTGCAGCCGTAGTCTTG R: CCAGGTCGTTGTGAGCTTCT
<i>FADD</i>	F: GCTGGCTCGTCAGCTCAAA R: ACTGTTGCGTTCCTCTCTCT
<i>TRADD</i>	F: GCTGTTGAGTTGCATCCTAGC R: CCGCACTTCAGATTTGCA
<i>Caspase-8</i>	F: TCTGGAGCATCTGCTGTCTG R: CCTGCCTGGTGTCTGAAGTT
<i>Caspase-10</i>	F: TAGGATTGGTCCCAACAAGA R: GAGAAACCCTTTGTCCGGGTGG
<i>MMP2</i>	F: TCTCCTGACATTGACCTTGCC R: CAAGGTGCTGGCTGAGTAGATC
<i>MMP9</i>	F: CCTGTGCTCTTCCCTGGAG R: GGCCCCAGAGATTTGACTC
<i>TIMP1</i>	F: ACCATGGCCCCCTTTGAGCCCTG R: TCAGGCTATCTGGGACCGCAGGGA
<i>TIMP2</i>	F: CTCGGCAGTGTGTGGGGTC R: CGAGAAACTCTGCTTGGGG

## Wound-healing assay

The control and dose group cells were plated at  $10^6$  cells per well of  $60 \times 15$  mm style cell culture dishes and grown overnight at  $37^\circ\text{C}$  with 5 %  $\text{CO}_2$ . The 80 % confluent control group and dose group cells were treated with 5  $\mu\text{M}$  exendin-4 after a straight line scratch was made on a confluent monolayer of cells using a sterile 200- $\mu\text{l}$  plastic pipette tip. To remove debris and smooth the edge of the scratch, the cells were washed with 2 ml serum-free DMEM. Images of the MCF-7 cell proliferation were taken at 0, 16, 24, and 48 h after the scratch. The scratch assay was performed in triplicate.

## Statistical analysis

The analysis of the findings has been made with the  $\Delta\Delta\text{CT}$  method and quantitated with a computer program. The comparison of the groups has been performed with “Volcano.Plot” analysis, from “RT<sup>2</sup>.ProfilesTMPCR Array Data Analysis”, which is assessed statistically using the “Student *t* test.” Moreover, parametric and non-parametric analysis of doses and controls has been evaluated with the SPSS 17.0 statistical analysis program ( $p < 0.05$  is significant statistically).

## Results


### Cytotoxic activity

#### *XTT assay*

MCF-7 cell death upon treatment with exendin-4 was assessed by the XTT (2,3-bis-(2-Metoksi-4-nitro-5-sülfofenil)-2H-tetrazolium-5-carboxanilide) assay. Time- and dose-dependent decrease patterns were found in the viability of MCF-7 cells. For this purpose, the expression changes of genes are evaluated by treating different concentration of exendin-4 at the 24th, 48th, and 72nd hour in MCF-7 cells. In our study,  $\text{IC}_{50}$  doses (inhibitory concentration where 50 % of the cells die) in the MCF-7 cells were detected as 5  $\mu\text{M}$  at 48th hour by XTT assay (Fig. 1).

### Real-time PCR

After total RNA was isolated from control and exendin-4-treated cells, the cDNA synthesis have been performed by using Transcriptor First-Strand cDNA Synthesis Kit (Roche Diagnostics, Germany). The expression analysis of *p53*, *caspase-3*, *caspase-9*, *caspase-8*, *caspase-10*, *Bcl-2*, *BCL-XL*, *BID*, *DR4*, *DR5*, *FADD*, *TRADD*, *PARP*, *APAF*, *Bax*, *Akt*, *PTEN*, *PUMA*, *NOXA*, *MMP2*, *MMP9*, *TIMP1*, *TIMP2* was studied on real-time RT-PCR according to the SYBR Green qPCR Master Mix (Thermo Scientific) protocol. Real-



**Fig. 1** Effect of exendin-4 on the viability of MCF-7 cells. The cells were treated with exendin-4 and at different concentrations and time intervals, and their proliferation was assessed by XTT assay. Data are the average results of three independent experiments. Asterisk  $IC_{50}$  dose of exendin-4 in MCF-7 breast cancer cells was detected 5  $\mu$ M/ml at 48th hour

time PCR analysis showed that *caspase-9*, *Akt*, and *MMP2* expression was reduced in dose group cells, compared with the control group cells. *p53*, *caspase-3*, *caspase-8*, *caspase-10*, *BID*, *DR4*, *DR5*, *FADD*, *TRADD*, *PARP*, *PTEN*, *PUMA*, *NOXA*, *APAF*, *TIMP1*, and *TIMP2* expression was increased in dose group cells, compared with the control group cells (Fig. 2a, b;  $p < 0.05$ ). *Akt*, *BCL-XL*, *BCL-2*, and *MMP-9* messenger RNA (mRNA) expressions were found statistically insignificant ( $p > 0.05$ ).

### Migration and invasion assay


By Matrigel invasion chamber assay, the cell invasion was significantly inhibited in the dose-treated group, compared with the control group. Invasive cells were shown in Fig. 3a. Data of invasion % of the two groups were shown as follow: control group ( $58 \pm 8.04$ ) % and dose group ( $37 \pm 5.2$ ) % (Fig. 3b).

### Colony formation assay

Colony formation analysis was performed by using colony formation assay. It is observed that the colony formation decreased in the 5  $\mu$ M exendin-4-treated group, compared with the control group (Fig. 4a). Data of colony numbers of the two groups were shown as follows: control group ( $525.3 \pm 12.34$ ) % and exendin-4 group ( $380.3 \pm 11.15$ ) % (Fig. 4b).

### Wound-healing assay

Effects of exendin-4 on cell migration were detected by wound-healing assay. According to results, exendin-4 reduced cell migration in MCF-7 cells, compared with the control group. Images at 0, 16, and 24 h were given in Fig. 5.




**Fig. 2 a** The mRNA expressions of genes relative to GAPDH mRNA expression were studied on real-time RT-PCR. The expression of these genes reduced in the exendin-4-treated cells, compared with the control cells. **b** Invasion related to mRNA gene expression change was demonstrated in the graph. These given mRNA fold changes were found statistically significant ( $p < 0.05$ ). mRNA changes of genes which were found statistically insignificant ( $p > 0.05$ ) were not shown

### Discussion


We report in this article that exendin-4 significantly inhibits the proliferation of MCF-7 breast cancer cells and induces apoptosis via the modulation of apoptosis-related genes which play a role in extrinsic pathway and cell survival genes. Furthermore, effects of exendin-4 on cell migration, cell invasion, and colony formation capacity were evaluated in this study. It was shown that it inhibits migration, cell invasion, and colony formation capacity of breast cancer cells.

Recent advances about incretin-based therapy including GLP-1R agonists and dipeptidyl peptidase-4 inhibition have enabled popularity in diabetes treatment throughout the world [18]. Incretin therapy has many advantages such as pancreatic  $\beta$  cell protection, lower risk of weight increase, and less hypoglycemic attacks [19]. Incretin therapy is also expected to have effects in tissue-conservation beyond its glucose-lowering capability [20, 21]. Recent studies demonstrated that exendin-4 has pleiotropic effects that extend beyond its hypoglycaemic activity and anticarcinogenic potential effects [9, 16, 17, 21].

**Fig. 3** **a** Migration and invasion assay of MCF-7 cells. Cells that passed through the membrane were counted in ten representative areas. **b** Summary graph for invasion were also shown respectively. Data was presented as mean±SD.  $n=3$ ,  $*p<0.05$




In a previous study, it is showed that exendin-4 has anti-carcinogenic effects in CT26 murine colon cancer cells by increasing increase intracellular cAMP levels and inhibiting glycogen synthase kinase 3 and ERK-MAPK activation, decreasing colony formation, and modulating apoptosis [17]. Luciani et al. defined the effects of exendin-4 on cell adhesion, differentiation, and migration of neuroblastoma cells. They demonstrated that GLP1-R stimulation inhibited migration of cells independently of the chemotactic stimulus used and also exendin-4 inhibited cell migration via IGF-1 and PDGF induction [16]. It has recently showed that exendin-4 has antitumor potential effects associated with production of cAMP in breast cancer [9]. Unlike previous studies, we focused on evaluating of exendin-4 and its molecular effect mechanisms related to apoptosis in MCF-7 cells. Invasion and migration are key process of tumor progression and closely related to breast cancer recurrence. Therefore, exendin-4 and its effects with underlying molecular mechanisms on invasion and migration were studied. Genes which play a role in extrinsic and intrinsic pathway of apoptosis were analyzed by RT-PCR and according to results, exendin-4 induced expressions of extrinsic pathway genes. Furthermore, exendin-4 reduced cell invasion by downregulating *MMP2* and upregulating *TIMP1* and *TIMP2* mRNA expressions.



**Fig. 4** **a** Exendin-4 decreases MCF-7 cell colony formation. Colonies were stained with crystal violet. **b** The number of colonies was significantly decreased in cells treated with exendin-4 compared with the control cells. Data are expressed as mean±SD,  $n=3$ ,  $*p<0.05$

**Fig. 5** Wound-healing assay results showed that exendin-4 reduced cell migration. Control and dose (5  $\mu$ M exendin-4) images at 0, 16, and 24 h were given



In many studies done through breast cancer patients, the results showed that obesity and T2DM have been related to breast cancer risk and poor prognosis [4–9]. DM and cancer share many common mechanisms, containing increased insulin and insulin-like growth factor (IGF) signaling, dysregulation of ovarian steroid hormones, and chronic inflammation [22–24]. Besides, other factors may be associated with T2DM being correlated with decreased postprandial secretion and GLP-1 activity [25–28]. Decreased GLP-1 levels which exist in diabetes may play a role between diabetes and increased risk of breast cancer [9].

Because of T2DM incidence increase day by day around the world, exposure to GLP-1R agonists may affect a lot of women. Studies about the effects of GLP-1R agonists on malignant diseases have been limited. Ligumsky et al. suggested in their study that there are not any association between GLP-1 agonists and the risk of breast cancer; conversely, GLP-1 agonists lead to proliferation, migration, cell invasion, and colony formation inhibition [9]. Due to complex molecular signaling pathways such as cell growth, survival, and invasion in breast cancer, the effects of GLP-1 on these pathways should be studied more in detail.

In conclusion, molecules that have been studied as potential anticancer agent for the improvement of treatment options are one of the most important research issues. For the determination of these novel agents, the molecular mechanisms related to apoptosis and cell survival of breast cancer cells need more studies. According to our results about the effects of exendin-4, this agent significantly inhibits the proliferation of MCF-7 breast cancer cells and induces apoptosis via the modulation of apoptosis-related genes which play a role in extrinsic pathway and cell survival genes. Furthermore, effects of exendin-4 on cell migration, cell invasion, and colony formation capacity were evaluated in this study. As a result, exendin-4 may be a novel potential agent and may play a role in the investigation of therapeutic strategies for breast cancer.

Therefore, more studies should be designed to find optimal safety dose of exendin-4 and to elucidate to underlying molecular effect mechanism.

#### Compliance with ethical standards

**Conflicts of interest** None

**Ethics approval and consent to participate** There is no need to take ethical approval and informed consent for this study.

#### References

1. Noto H, Tsujimoto T, Sasazuki T, Noda M. Significantly increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis. *Endocr Pract.* 2011;17(4):616–28.
2. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. *JAMA.* 2008;300(23):2754–64.
3. Peairs KS, Barone BB, Snyder CF, Yeh HC, Stein KB, Derr RL, et al. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. *J Clin Oncol.* 2011;29(1):40–6.
4. Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B. Diabetes mellitus and breast cancer. *Lancet Oncol.* 2005;6:103–11.
5. Eliassen AH, Tworoger SS, Mantzoros CS, Pollak MN, Hankinson SE. Circulating insulin and C-peptide levels and risk of breast cancer among predominately premenopausal women. *Cancer Epidemiol Biomarkers Prev.* 2007;16:161–4.
6. Schernhammer ES, Holly JM, Pollak MN, Hankinson SE. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. *Cancer Epidemiol Biomarkers Prev.* 2005;14:699–704.
7. Wolf I, Sadetzki S, Gluck I, Oberman B, Ben-David M, Papa MZ, et al. Association between diabetes mellitus and adverse characteristics of breast cancer at presentation. *Eur J Cancer.* 2006;42:1077–82.
8. Yee D. Targeting insulin-like growth factor pathways. *Br J Cancer.* 2006;94:465–8.
9. Ligumsky H, Wolf I, Israeli S, Haimsohn M, Ferber S, Karasik A, et al. The peptidehormone glucagon-like peptide-1 activates cAMP

- and inhibits growth of breast cancer cells. *Breast Cancer Res Treat.* 2012;132:449–61.
10. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. *Gastroenterology.* 2007;132:2131–57.
  11. Dufayet de la Tour D, Halvorsen T, Demeterco C, Tyrberg B, Itkin-Ansari P, Loy M, et al.  $\beta$ -Cell differentiation from a human pancreatic cell line in vitro and in vivo. *Mol Endocrinol.* 2001;15:476–83.
  12. Holst JJ, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. *Mol Cell Endocrinol.* 2009;297:127–36.
  13. Idris I, Patiag D, Gray S, Donnelly R. Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism: contrasting effects of GLP-1. *Biochem Pharmacol.* 2002;63:993–6.
  14. Lee YS, Shin S, Shigihara T, Hahm E, Liu MJ, Han J, et al. Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis. *Diabetes.* 2007;56(6):1671–9.
  15. Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. *Am J Health Syst Pharm.* 2005;62:173–81.
  16. Luciani P, Deledda C, Benvenuti S, Squecco R, Cellai I, Fibbi B, et al. Exendin 4 induces cell adhesion and differentiation and counteracts the invasive potential of human neuroblastoma cells. *PLoS One.* 2013;22:8(8).
  17. Koehler JA, Kain T, Drucker DJ. Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells. *Endocrinology.* 2011;152:3362–72.
  18. Mikhail N. Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes. *Curr Drug Saf.* 2011;6:304–9.
  19. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. *Diabetes Care.* 2003;26:2929–40.
  20. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. *Endocr Rev.* 2012;33:187–215.
  21. Nomiya T, Kawanami T, Irie S, Hamaguchi Y, Terawaki Y, Murase K, et al. Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth. *Diabetes.* 2014;63(11):3891–905.
  22. Korner A, Pazaitou-Panayiotou K, Kelesidis T, Kelesidis I, Williams CJ, Kaprara A, et al. Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. *J Clin Endocrinol Metab.* 2007;92:1041–8.
  23. Novosyadlyy R, Lann DE, Vijayakumar A, Rowzee A, Lazzarino DA, Fierz Y, et al. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. *Cancer Res.* 2010;70:741–51.
  24. Joung KH, Jeong JW, Ku BJ. The association between type 2 diabetes mellitus and women cancer: the epidemiological evidences and putative mechanisms. *Biomed Res Int.* 2015;2015:920618.
  25. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. *Diabetes.* 2001;50:609–13.
  26. Toft-Nielsen M-B, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. *J Clin Endocrinol Metab.* 2001;86:3717–23.
  27. Kjems LL, Holst JJ, Volund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion. *Diabetes.* 2003;52:380–6.
  28. Carr RD, Larsen MO, Jelic K, Lindgren O, Vikman J, Holst JJ, et al. Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men. *J Clin Endocrinol Metab.* 2009;95(2):872–8.